Nanomedicine and Neurosciences : Advantages, limitations and safety aspects /

Saved in:
Bibliographic Details
Imprint:Sharjah : Bentham Science Publishers, 2017.
Description:1 online resource (285 pages)
Language:English
Series:Frontiers in Nanomedicine ; v. 2
Frontiers in Nanomedicine ; v. 2.
Subject:Medical technology.
Nanotechnology.
Medical innovations.
HEALTH & FITNESS -- Holism.
HEALTH & FITNESS -- Reference.
MEDICAL -- Alternative Medicine.
MEDICAL -- Atlases.
MEDICAL -- Essays.
MEDICAL -- Family & General Practice.
MEDICAL -- Holistic Medicine.
MEDICAL -- Osteopathy.
Medical innovations.
Medical technology.
Nanotechnology.
Electronic books.
Format: E-Resource Book
URL for this record:http://pi.lib.uchicago.edu/1001/cat/bib/11758938
Hidden Bibliographic Details
Other authors / contributors:Tosi, Giovanni.
ISBN:1681084937
9781681084930
Notes:Neuronopathic LSDs: Quest for Treatments Drives Research in Nanomedicine and Nanotechnology.
Includes bibliographical references and index.
Print version record.
Other form:Print version: Tosi, Giovanni. Nanomedicine and Neurosciences: Advantages, Limitations and Safety Aspects. Sharjah : Bentham Science Publishers, ©2017 9781681084947
Table of Contents:
  • FOREWORD ; PREFACE ; List of Contributors ; Nanomedicine and Neurodegenerative Diseases: An Introduction to Pathology and Drug Targets ; Tasnuva Sarowar1 and Andreas M. Grabrucker2,*; INTRODUCTION; CLINICAL REPRESENTATIONS; Alzheimer's Disease; Core Features of AD; Symptoms & Diagnosis of AD; Parkinson's Disease; Symptoms & Core Features of PD; Diagnosis of PD; Amytropohic Lateral Sclerosis; Core Features of ALS; Symptoms & Diagnosis of ALS; ANATOMY AND PATHOLOGY; Initiation and Progression; Alzheimer's Disease; Parkinson's Disease; Other Neurodegenerative Disorders.
  • Brain Morphology, Cellular Pathology and Neurobiology of the DiseaseAlzheimer's Disease; Parkinson's Disease; Amyloid Lateral Sclerosis; GENES AND ENVIRONMENT; ; Genetics of Neurodegenerative Diseases; Candidate Genes for Alzheimer's Disease; Parkinson's Disease; Candidate Genes for Parkinson's Disease; Candidate Genes for ALS; Environmental Risk Factors; Trace Metal Alterations; Other Risk Factors; ANIMAL MODELS; Animal Models for AD; Animal Models for PD; Animal Models for ALS; Animal Models for HD; DRUG TARGETS IN NEURODEGENERATIVE DISORDERS; Drug Targets in AD; Drug Targets in PD.
  • TREATMENT OF NEURODEGENERATIVE DISORDERS USING NANOMEDICINECONCLUSIONS; CONFLICT OF INTEREST; ACKNOWLEDGEMENT; REFERENCES; Nanoparticles Targeting Mitochondria in Neurodegenerative Diseases: Toxicity and Challenge for Nanotherapeutics ; Michal Cagalinec*; INTRODUCTION AND OVERVIEW; ALZHEIMER'S AND PARKINSON'S DISEASE; MITOCHONDRIA; MITOCHONDRIAL FUSION AND FISSION; NANOPARTICLES AND THE BRAIN; NANOPARTICLES' TOXICITY, FOCUS ON NEUROTOXICITY; NANOPARTICLES AS DRUG CARRIERS; MITOCHONDRIA AND ALZHEIMER'S DISEASE; MITOCHONDRIA AND PARKINSON'S DISEASE.
  • NANOPARTICLES AND ALZHEIMER'S DISEASE TREATMENTNANOPARTICLES AND PARKINSON'S DISEASE TREATMENT; NANOPARTICLES AS DRUG DELIVERY SYSTEMS TO MITO- CHONDRIA; COULD NANOPARTICLES IMPROVE MITOCHONDRIAL FUNCTION- ING WITHOUT ENTERING MITOCHONDRIA?; FUTURE DIRECTIONS, PERSPECTIVES, LIMITATIONS; CONCLUSIONS; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; ABBREVIATIONS; REFERENCES; Neuronal Mechanisms for Nanotopography Sensing ; Ilaria Tonazzini1,2 and Marco Cecchini1,*; INTRODUCTION; Focal Adhesions and Cytoskeleton during Neuronal Cell-nanograting Interaction.
  • Neuronal Differentiation Drives Nanotopography SensingNoise Tolerance in Neuronal Contact Guidance; CONCLUSIONS; CONFLICT OF INTEREST; ACKNOWLEDGMENTS; REFERENCES; Drug Delivery to the Brain by Liposomal Carrier Systems ; Anne Mahringer and Gert Fricker*; INTRODUCTION; LIPOSOMES; TRANSFERRIN RECEPTOR; INSULIN RECEPTOR; LDL RECEPTOR; LEPTIN RECEPTOR; RECEPTOR OF ADVANCED GLYCATION END PRODUCTS; ABSORPTIVE-MEDIATED TRANSCYTOSIS ACROSS THE BBB; ULTRASOUND AND LIPOSOMES TO OVERCOME THE BBB; CONCLUSION; CONFLICT OF INTEREST; ACKNOWLEDGMENTS; REFERENCES.